Academic Journal
Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale)
| العنوان: | Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale) |
|---|---|
| المؤلفون: | Lorusso, V., Spada, M., Giampaglia, M., Misino, A., Calabrese, R., Latorre, A., Monticelli, G., Guida, M., Sambiasi, D., Colucci, G. |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2006 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | part I: invited papers, breast and ovarian cancer |
| الوصف: | Background: Vinorelbine i.v. and capecitabine are two of the most effective single agents in previously treated advanced breast cancer (ABC). A number of studies have been reported with the combination of these agents. Actually, the availability of oral formulation for vinorelbine allows a full oral combination of the two agents. The aim of this study was to evaluate the activity and toxicity of this novel combination. Patients and methods: Thirty-eight advanced breast cancer patients refractory to anthracyclines and taxanes were included in this study. Treatment consisted of vinorelbine 60 mg/m2 (days 1 + 8), and capecitabine 2000 mg/m2 (days 2–7 and 9–16) every 3 weeks. Results: A total of 228 courses were given with a mean of three cycles/patient (range 1–12). Five patients (13.1%) had no toxicity at all. Hematologic side-effects were: neutropenia grade 2–3 in seven patients (18.9%) and grade 4 in one patient (2.7%), anemia grade 1 in 11 patients (29.7%), grade 2–3 in five patients (13.5%), thrombocytopenia grade 1 in six patients (16.2%) and grade 3 in one patient (2.7%). Non-hematologic side-effects were: fatigue grade 1 in five patients (13.5%), hand–foot syndrome grade 1 in two patients (5.4%) and grade 2 in two patients (5.4%), nausea/vomiting grade 1 in two patients (5.4%), grade 2 in three patients (8.1%) and grade 3 in one patient (2.7%), constipation grade 1 in two patients (5.4%), peripheral neurotoxicity grade 1 in three patients (8.1%) and grade 2 in one patient (2.7%), gastric pain grade 1 in two patients (5.4%), stomatitis grade 1 in three patients (8.1%) and grade 2 in one patient (2.7%). Out of 38 patients assessable, we observed two (5.4%) CR, 13 (34 %) PR, 14 (37.8%) SD and nine (26.3%) PD. The median time to progression was 4.5 months (range 1–18 months), the median response duration was 7 months (range 2–18 months) and the median survival duration was 10 months (range 2–26+). Conclusions: The oral vincap should be considered as an alternative to single agent capecitabine or vinorelbine in ... |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| Relation: | http://annonc.oxfordjournals.org/cgi/content/short/17/suppl_7/vii15; http://dx.doi.org/10.1093/annonc/mdl942 |
| DOI: | 10.1093/annonc/mdl942 |
| الاتاحة: | http://annonc.oxfordjournals.org/cgi/content/short/17/suppl_7/vii15 https://doi.org/10.1093/annonc/mdl942 |
| Rights: | Copyright (C) 2006, European Society for Medical Oncology |
| رقم الانضمام: | edsbas.29864688 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/annonc/mdl942 |
|---|